Protection by zinc-metallothionein (ZnMT) against cadmium-metallothionein-induced nephrotoxicity.
In contrast to inorganic Cd, acute iv administration of Cd bound to metallothionein (CdMT) concentrates in renal tissue. This uptake of CdMT produces functional and morphological changes in kidneys, similar to those observed after chronic exposure to inorganic Cd. In order to examine the importance of the metal component of MT in the renal uptake of MT, the renal concentration of 35S after administration of [35S]ZnMT and [35S]CdMT was compared. Renal uptake of 35S from both CdMT and ZnMT was very rapid, with peak concentrations observed 15-30 min after administration. 35S in kidneys increased in a dose-dependent manner after administration of various doses of [35S]ZnMT, up to 1.3 mumole MT/kg; however, higher doses did not further increase renal 35S concentrations. A similar saturation of 35S reabsorption was observed for the renal uptake of [35S]CdMT. CdMT produced renal injury with doses as low as 0.26 mumol MT/kg (0.2 mg Cd/kg). In contrast, with a dose of ZnMT as high as 5.12 mumol MT/kg (2 mg Zn/kg), no histopathological changes were observed. Therefore, ZnMT appears to be nontoxic even though ZnMT delivers more MT to the kidney than does CdMT. Because ZnMT and CdMT are apparently handled by the same renal transport mechanism, the effects of ZnMT on 109CdMT renal uptake and nephrotoxicity were determined. One group of mice was given a nephrotoxic dose of 109CdMT (0.51 mumol MT/kg containing 0.4 mg Cd/kg, i.v.), and the other group received an equimolar dose of unlabeled ZnMT 1 min before 109CdMT administration. Renal function was evaluated by measuring urinary glucose and protein excretion, as well as histopathology.(ABSTRACT TRUNCATED AT 250 WORDS)
Dorian
C
C
Department of Pharmacology, Toxicology and Therapeutics, University of Kansas Medical Center, Kansas City 66160-7417, USA.
Klaassen
C D
CD
D000818:Animals; D002104:Cadmium / Q000493:pharmacokinetics / Q000633:toxicity*; D004305:Dose-Response Relationship, Drug; D007668:Kidney / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D007674:Kidney Diseases / Q000139:chemically induced* / Q000517:prevention & control; D008099:Liver / Q000378:metabolism; D008297:Male; D008668:Metallothionein / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000633:toxicity*; D051379:Mice; D051381:Rats; D015032:Zinc / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000633:toxicity
C004203:cadmium-binding protein; C021267:zinc thionein; D002104:Cadmium; D008668:Metallothionein; D015032:Zinc